- Home
- CALC vs ACRV Comparison
CALC vs ACRV Comparison
Compare CALC & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- ACRV
- Stock Information
- Founded
- CALC 2011
- ACRV 2018
- Country
- CALC United States
- ACRV United States
- Employees
- CALC N/A
- ACRV N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- CALC Health Care
- ACRV Health Care
- Exchange
- CALC Nasdaq
- ACRV Nasdaq
- Market Cap
- CALC 48.1M
- ACRV 41.7M
- IPO Year
- CALC N/A
- ACRV 2022
- Fundamental
- Price
- CALC $2.91
- ACRV $1.35
- Analyst Decision
- CALC Strong Buy
- ACRV Buy
- Analyst Count
- CALC 2
- ACRV 7
- Target Price
- CALC $14.50
- ACRV $17.40
- AVG Volume (30 Days)
- CALC 91.2K
- ACRV 253.4K
- Earning Date
- CALC 08-12-2025
- ACRV 08-13-2025
- Dividend Yield
- CALC N/A
- ACRV N/A
- EPS Growth
- CALC N/A
- ACRV N/A
- EPS
- CALC N/A
- ACRV N/A
- Revenue
- CALC N/A
- ACRV N/A
- Revenue This Year
- CALC N/A
- ACRV N/A
- Revenue Next Year
- CALC N/A
- ACRV $1,037.93
- P/E Ratio
- CALC N/A
- ACRV N/A
- Revenue Growth
- CALC N/A
- ACRV N/A
- 52 Week Low
- CALC $1.42
- ACRV $1.05
- 52 Week High
- CALC $5.97
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- CALC 52.85
- ACRV 53.72
- Support Level
- CALC $2.31
- ACRV $1.20
- Resistance Level
- CALC $3.00
- ACRV $1.32
- Average True Range (ATR)
- CALC 0.34
- ACRV 0.09
- MACD
- CALC -0.12
- ACRV 0.00
- Stochastic Oscillator
- CALC 40.00
- ACRV 60.00
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.